Serologicals Corporation Announces Expanded Multi-Year Distribution Agreement With Novo Nordisk A/S

Published: Mar 16, 2006

ATLANTA--(BUSINESS WIRE)--March 16, 2006--Celliance Corporation, a wholly owned subsidiary of Serologicals Corporation (NASDAQ:SERO), announced today the execution of an expanded four-year supply agreement with Novo Nordisk A/S that provides Celliance the worldwide exclusive right to distribute Novo Nordisk's recombinant human insulin in the cell culture market.

Back to news